Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

作者：Henry N Lynn; Rae James M; Li Lang; Azzouz Faouzi; Skaar Todd C; Desta Zereunesay; Sikora Matthew J; Philips Santosh; Nguyen Anne T; Storniolo Anna Maria; Hayes Daniel F; Flockhart David A; Stearns Vered^*

来源：Breast Cancer Research and Treatment, 2009, 117(3): 571-575.

DOI：10.1007/s10549-009-0309-1

• Breast cancer
• Tamoxifen
• CYP2D6
• Hot flash
• Genotype

Women with reduced CYP2D6 activity have low endoxifen concentrations and likely worse long term benefits from tamoxifen. We investigated the association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. We collected hot flash frequency and severity data over 12 months from 297 women initiating tamoxifen. We performed CYP2D6 genotyping using the AmpliChip CYP450 test and correlated inherited genetic polymorphisms in CYP2D6 and tamoxifen-induced hot flashes. Intermediate metabolizers had greater mean hot flash scores after 4 months of tamoxifen therapy (44.3) compared to poor metabolizers (20.6, P = 0.038) or extensive metabolizers (26.9, P = 0.011). At 4 months, we observed a trend toward fewer severe hot flashes in poor metabolizers compared to intermediate plus extensive metabolizers (P = 0.062). CYP2D6 activity may be a modest predictive factor for tamoxifen-induced hot flashes. The presence or absence of hot flashes should not be used to determine tamoxifen's efficacy.

• 出版日期2009-10